Merck & Co., Inc. | Large-cap | Healthcare
$79.07
0.30%
| Merck & Co Stock Comparison:
Merck & Co vs Eli Lilly andMerck & Co vs Johnson & JohnsonMerck & Co vs AmgenMerck & Co vs Gilead SciencesMerck & Co vs PfizerMerck & Co vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 64.2B
Gross Profit 49.0B 76.32%
Operating Income 20.2B 31.51%
Net Income 17.1B 26.70%
EPS (Diluted) $6.74

Balance Sheet Metrics

Total Assets 117.1B
Total Liabilities 70.7B
Shareholders Equity 46.4B
Debt to Equity 1.53

Cash Flow Metrics

Operating Cash Flow 22.7B
Free Cash Flow 18.1B

Revenue & Profitability Trend

Merck & Co Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 64.2B 60.1B 59.3B 48.7B 41.5B
Cost of Goods Sold 15.2B 16.1B 17.4B 13.6B 13.6B
Gross Profit 49.0B 44.0B 41.9B 35.1B 27.9B
Operating Expenses 28.8B 41.0B 23.6B 21.9B 22.4B
Operating Income 20.2B 3.0B 18.3B 13.2B 5.5B
Pre-tax Income 19.9B 1.9B 16.4B 13.9B 5.9B
Income Tax 2.8B 1.5B 1.9B 1.5B 1.3B
Net Income 17.1B 377.0M 14.5B 13.1B 7.1B
EPS (Diluted) $6.74 $0.14 $5.71 $5.14 $2.78

Income Statement Trend

Merck & Co Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 38.8B 32.2B 35.7B 30.3B 27.8B
Non-Current Assets 78.3B 74.5B 73.4B 75.4B 63.8B
Total Assets 117.1B 106.7B 109.2B 105.7B 91.6B
Liabilities
Current Liabilities 28.4B 25.7B 24.2B 23.9B 27.3B
Non-Current Liabilities 42.3B 43.3B 38.9B 43.6B 38.9B
Total Liabilities 70.7B 69.0B 63.1B 67.4B 66.2B
Equity
Total Shareholders Equity 46.4B 37.6B 46.1B 38.3B 25.4B

Balance Sheet Composition

Merck & Co Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income 17.1B 377.0M 14.5B 12.4B 4.5B
Operating Cash Flow 22.7B 10.6B 15.6B 15.0B 7.6B
Investing Activities
Capital Expenditures - - - - -
Investing Cash Flow -4.4B -10.2B -572.0M -12.0B -4.8B
Financing Activities
Dividends Paid -7.8B -7.4B -7.0B -6.6B -6.2B
Financing Cash Flow -7.2B -4.9B -9.5B 2.9B -2.9B
Free Cash Flow 18.1B 9.1B 14.7B 9.7B 5.8B

Cash Flow Trend

Merck & Co Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 11.49
Forward P/E 8.41
Price to Book 4.12
Price to Sales 3.11
PEG Ratio 8.41

Profitability Ratios

Profit Margin 27.27%
Operating Margin 40.06%
Return on Equity 39.29%
Return on Assets 13.81%

Financial Health

Current Ratio 1.41
Debt to Equity 71.99
Beta 0.44

Per Share Data

EPS (TTM) $6.88
Book Value per Share $19.21
Revenue per Share $25.27

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
mrk 198.5B 11.49 4.12 39.29% 27.27% 71.99
Eli Lilly and 691.8B 62.76 46.33 77.28% 22.67% 243.61
Johnson & Johnson 364.1B 16.83 4.66 29.45% 24.42% 66.90
Amgen 146.5B 24.84 23.60 105.67% 17.39% 924.46
Gilead Sciences 132.1B 22.31 6.90 32.65% 20.76% 130.79
Pfizer 136.6B 17.41 1.51 8.62% 12.62% 68.84

Financial data is updated regularly. All figures are in the company's reporting currency.